Key stats
About Yinhua China Sec Hong Kong Stock Connect Innovative Drug Etf
Home page
Inception date
Jan 3, 2024
Structure
Open-Ended Fund
China Securities Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Gross
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
Yinhua Fund Management Co., Ltd.
Identifiers
2
ISINCNE100006D34
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Cash
Stocks80.26%
Health Technology78.12%
Commercial Services2.14%
Bonds, Cash & Other19.74%
Cash11.70%
Miscellaneous8.04%
Stock breakdown by region
Asia100.00%
North America0.00%
Latin America0.00%
Europe0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
159567 invests in stocks. The fund's major sectors are Health Technology, with 78.12% stocks, and Commercial Services, with 2.14% of the basket. The assets are mostly located in the Asia region.
No, 159567 doesn't pay dividends to its holders.
159567 shares are issued by Yinhua Fund Management Co., Ltd. under the brand Yinhua. The ETF was launched on Jan 3, 2024, and its management style is Passive.
159567 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
159567 follows the China Securities Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
159567 invests in stocks.
159567 trades at a premium (0.08%) meaning the ETF is trading at a higher price than the calculated NAV.